Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective studySi Houn Hahn, Priya S. Kishnani, Kristina An Haack et al.|Genetics in Medicine|2018Cited by 31
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe diseasePriya S. Kishnani, Si Houn Hahn, James B. Gibson et al.|Genetics in Medicine|2019Cited by 16
Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohortBarry J. Byrne, Raymond Wang, Steven D. Colan et al.|Cardiology in the Young|2021Cited by 15
Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant CohortPriya S. Kishnani, Kristina An Haack, Meredith C. Foster et al.|Journal of Neuromuscular Diseases|2022Cited by 5
Clinical characteristics and genotypes in the ADVANCE baseline dataset, a comprehensive cohort of us children and youth with Pompe diseasePriya S. Kishnani, Sihoun Hahn, Michael J. Gambello et al.|Molecular Genetics and Metabolism|2016Cited by 1